Prior-Art / FTO Structural Triage
Fast first-pass structure search across many patents (also covers CDMO process pre-screens).
Don't see the patent you're looking for? We'll run it and email you within 1 hour.
US10590130B2: camizestrant cross-references 65 other patent(s) via PubChem structural search (6 likely-same-scaffold hit(s))
Real cross-patent screening for US10590130B2 (AstraZeneca AB, 'Chemical compounds'). Target compound camizestrant resolved to canonical SMILES and screened against PubChem's patent-compound index. Result: 65 unique other patents reference structurally near-identical (6 hits) or related-scaffold (6 hits) compounds. Search completed in 21.0s. Structural overlap only; no infringement conclusion stated.
US10501515B2: rusfertide cross-references 69 other patent(s) via PubChem structural search (6 likely-same-scaffold hit(s))
Real cross-patent screening for US10501515B2 (Protagonist Therapeutics Inc, 'Hepcidin analogues and uses thereof'). Target compound rusfertide resolved to canonical SMILES and screened against PubChem's patent-compound index. Result: 69 unique other patents reference structurally near-identical (6 hits) or related-scaffold (6 hits) compounds. Search completed in 30.8s. Structural overlap only; no infringement conclusion stated.
US11807629B2: selinexor cross-references 90 other patent(s) via PubChem structural search (6 likely-same-scaffold hit(s))
Real cross-patent screening for US11807629B2 (Karyopharm Therapeutics Inc., 'Crystalline forms of Selinexor'). Target compound selinexor resolved to canonical SMILES and screened against PubChem's patent-compound index. Result: 90 unique other patents reference structurally near-identical (6 hits) or related-scaffold (6 hits) compounds. Search completed in 26.3s. Structural overlap only; no infringement conclusion stated.
US12702644B2: ibuprofen cross-references 60 other patent(s) via PubChem structural search (6 likely-same-scaffold hit(s))
Real cross-patent screening for US12702644B2 (Chiesi Farmaceutici S.p.A., 'Pharmaceutical composition comprising ibuprofen and arginine'). Target compound ibuprofen resolved to canonical SMILES and screened against PubChem's patent-compound index. Result: 60 unique other patents reference structurally near-identical (6 hits) or related-scaffold (6 hits) compounds. Search completed in 39.3s. Structural overlap only; no infringement conclusion stated.
US12629338B1: tenofovir cross-references 96 other patent(s) via PubChem structural search (5 likely-same-scaffold hit(s))
Live PubChem cross-patent search (fastsimilarity_2d + xrefs/PatentID, the same method used in production for the Instant Compound Check) found 5 structurally near-identical compound(s) and 5 related-scaffold compound(s) already cross-referenced to 96 other patent(s) across PubChem's indexed sources (SureChEMBL and others). (2 additional similar-compound lookup(s) timed out, not counted as confirmed) Sourced from US12629338B1 (Gilead Sciences Inc), compound identified via named-compound resolution (patent text → PubChem).
US12629369B2: nilotinib cross-references 110 other patent(s) via PubChem structural search (6 likely-same-scaffold hit(s))
Live PubChem cross-patent search (fastsimilarity_2d + xrefs/PatentID, the same method used in production for the Instant Compound Check) found 6 structurally near-identical compound(s) and 5 related-scaffold compound(s) already cross-referenced to 110 other patent(s) across PubChem's indexed sources (SureChEMBL and others). (1 additional similar-compound lookup(s) timed out, not counted as confirmed) Sourced from US12629369B2 (Azurity Pharmaceuticals Inc), compound identified via named-compound resolution (patent text → PubChem).
US12629343B2: ibuprofen cross-references 40 other patent(s) via PubChem structural search (2 likely-same-scaffold hit(s))
Live PubChem cross-patent search (fastsimilarity_2d + xrefs/PatentID, the same method used in production for the Instant Compound Check) found 2 structurally near-identical compound(s) and 2 related-scaffold compound(s) already cross-referenced to 40 other patent(s) across PubChem's indexed sources (SureChEMBL and others). (8 additional similar-compound lookup(s) timed out, not counted as confirmed) Sourced from US12629343B2 (Demotech Inc), compound identified via named-compound resolution (patent text → PubChem).
US12703702B2: tofacitinib cross-references 89 other patent(s) via PubChem structural search (5 likely-same-scaffold hit(s))
Live PubChem cross-patent search (fastsimilarity_2d + xrefs/PatentID, the same method used in production for the Instant Compound Check) found 5 structurally near-identical compound(s) and 4 related-scaffold compound(s) already cross-referenced to 89 other patent(s) across PubChem's indexed sources (SureChEMBL and others). (3 additional similar-compound lookup(s) timed out, not counted as confirmed) Sourced from US12703702B2 (AARTI PHARMALABS LIMITED), compound identified via named-compound resolution (patent text → PubChem).
US12187700B2: NLDMNSXOCDLTTB-UHFFFAOYSA-N cross-references 88 other patent(s) via PubChem structural search (5 likely-same-scaffold hit(s))
Live PubChem cross-patent search (fastsimilarity_2d + xrefs/PatentID, the same method used in production for the Instant Compound Check) found 5 structurally near-identical compound(s) and 4 related-scaffold compound(s) already cross-referenced to 88 other patent(s) across PubChem's indexed sources (SureChEMBL and others). (3 additional similar-compound lookup(s) timed out, not counted as confirmed) Sourced from US12187700B2 (Amgen Inc), compound identified via Google Patents' own disclosed-compound data.
US12709595B2: belzutifan cross-references 70 other patent(s) via PubChem structural search (6 likely-same-scaffold hit(s))
Live PubChem cross-patent search (fastsimilarity_2d + xrefs/PatentID, the same method used in production for the Instant Compound Check) found 6 structurally near-identical compound(s) and 3 related-scaffold compound(s) already cross-referenced to 70 other patent(s) across PubChem's indexed sources (SureChEMBL and others). (3 additional similar-compound lookup(s) timed out, not counted as confirmed) Sourced from US12709595B2 (Merck Sharp & Dohme LLC), compound identified via named-compound resolution (patent text → PubChem).
US12629337B2: Daptomycin cross-references 100 other patent(s) via PubChem structural search (6 likely-same-scaffold hit(s))
Live PubChem cross-patent search (fastsimilarity_2d + xrefs/PatentID, the same method used in production for the Instant Compound Check) found 6 structurally near-identical compound(s) and 4 related-scaffold compound(s) already cross-referenced to 100 other patent(s) across PubChem's indexed sources (SureChEMBL and others). (2 additional similar-compound lookup(s) timed out, not counted as confirmed) Sourced from US12629337B2 (Hikma Pharmaceuticals USA Inc), compound identified via named-compound resolution (patent text → PubChem).
US12187719B2: OSWFIVFLDKOXQC-UHFFFAOYSA-N cross-references 80 other patent(s) via PubChem structural search (6 likely-same-scaffold hit(s))
Live PubChem cross-patent search (fastsimilarity_2d + xrefs/PatentID, the same method used in production for the Instant Compound Check) found 6 structurally near-identical compound(s) and 2 related-scaffold compound(s) already cross-referenced to 80 other patent(s) across PubChem's indexed sources (SureChEMBL and others). (4 additional similar-compound lookup(s) timed out, not counted as confirmed) Sourced from US12187719B2 (Boehringer Ingelheim International GmbH), compound identified via Google Patents' own disclosed-compound data.
Frequently asked
What is FTO Structural Triage?
A fast first-pass freedom-to-operate screen: search a target compound or synthetic route against the existing patent landscape before committing R&D or manufacturing spend.
How fast is it?
It's automated: the $10 Instant Compound Check on an arbitrary patent typically returns within about an hour.
Does it work for CDMO process patents too?
Yes: the same engine also powers a dedicated CDMO process pre-screen page.